Skip to content
  1. Home/
  2. Latest news

Latest news

Johnson & Johnson named to Fortune‘s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

More from Johnson & Johnson

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers

Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.

Careers

Looking for a career opportunity at Johnson & Johnson? Search our available jobs.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

What is metastatic cancer?

The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.

“The surgical devices I design help speed healing and save lives”

Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.

Press releases

Johnson & Johnson expands efforts to champion the nursing workforce globally

New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges

Johnson & Johnson’s New “Oncology Care Index” Highlights the Growing Divide Between Cancer Innovation and Implementation in Clinical Practice

73% of surveyed HCPs say there’s a gap between the availability of new, cutting-edge treatments and their successful implementation in clinical practice; 3 in 4 oncologists find the pace of new treatment development overwhelming Insights will boost Johnson & Johnson’s strong approach to supporting oncologists with the resources and opportunities needed to enhance patient care and stay informed on emerging treatments.

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn’s disease

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92

Johnson & Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE)

More from Johnson & Johnson

Johnson & Johnson named a 2025 Fortune World’s Most Admired Company

A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.

What you need to know about Johnson & Johnson’s 2024 fourth-quarter and full-year earnings report

Check out this infographic breakdown of the company’s fourth-quarter and full-year performance, with highlights from its Innovative Medicine and MedTech businesses.

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.